Brief: FDA Says Is Informing Health Care Providers About Potential Biocompatibility Concerns Associated With NuVasive Specialized Orthopedics’ Precice Devices
July 8 (Reuters) - FDA:
* FDA SAYS IS INFORMING HEALTH CARE PROVIDERS ABOUT
POTENTIAL
BIOCOMPATIBILITY CONCERNS ASSOCIATED WITH NUVASIVE SPECIALIZED
ORTHOPEDICS’ PRECICE DEVICES
* FDA SAYS NUVASIVE IS PERFORMING ADDITIONAL
BIOCOMPATIBILITY
TESTING ON MATERIALS USED FOR ALL PRECICE DEVICES AGAINST
UPDATED TESTING STANDARDS
* FDA SAYS NUVASIVE IS ALSO CONDUCTING SERIES OF ASSESSMENTS
OF
POTENTIAL MECHANICAL FAILURES THAT MAY CONTRIBUTE TO
BIOCOMPATIBILITY ISSUES
Further company coverage: NUVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NuVasive
See all newsJackson Financial to join small-cap S&P 600; shares climb
NuVasive Inc reports results for the quarter ended in June - Earnings Summary
Brief: NuVasive Q2 Adjusted EPS USD 0.56 Vs. IBES Estimate USD 0.55
NuVasive Inc expected to post earnings of 55 cents a share - Earnings Preview
Brief: NuVasive Borrows $350 Mln In Revolving Loans Under 2020 Facility